Find Reports

Select Report Type

Reimbursement Review

Displaying 76 - 100 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
dostarlimab	Jemperli	dostarlimab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Endometrial cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 18, 2023	May 3, 2024	PC0325-000
cemiplimab	Libtayo	cemiplimab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Locally advanced or metastatic NSCLC (first line)	Reimburse with clinical criteria and/or conditions	Complete	Sep 27, 2023	May 2, 2024	PC0331-000
maralixibat	Livmarli	maralixibat	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Alagille syndrome	Reimburse with clinical criteria and/or conditions	Complete	May 5, 2023	Apr 22, 2024	SR0780-000
infliximab	Remsima	infliximab	Recommendation and Reason Patient and Clinician Group input	Ulcerative Colitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2023	Apr 22, 2024	SR0816-001
infliximab	Remsima	infliximab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Crohn’s disease	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2023	Apr 22, 2024	SR0816-000
inclisiran	Leqvio	inclisiran	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Primary hypercholesterolemia	Do not reimburse	Complete	Sep 19, 2023	Apr 22, 2024	SR0791-001
etranacogene dezaparvovec	Hemgenix	etranacogene dezaparvovec	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Hemophilia B	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2023	Apr 19, 2024	SG0805-000
everolimus	N/A	everolimus	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Responses to Questions From the Drug Programs Stakeholder Input	Renal angiomyolipoma associated with tuberous sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Jul 6, 2023	Apr 18, 2024	SX0814-000
panitumumab	N/A	panitumumab	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder input	Left-sided metastatic colorectal cancer (mCRC)	Reimburse with clinical criteria and/or conditions	Complete	May 19, 2023	Apr 18, 2024	PX0333-000
cannabidiol	Epidiolex	cannabidiol	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Lennox-Gastaut Syndrome (LGS)	Reimburse with clinical criteria and/or conditions	Complete	Sep 20, 2023	Apr 18, 2024	SR0800-000
cannabidiol	Epidiolex	cannabidiol	Recommendation and Reasons Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Dravet Syndrome (DS)	Reimburse with clinical criteria and/or conditions	Complete	Sep 25, 2023	Apr 18, 2024	SR0799-000
cannabidiol	Epidiolex	cannabidiol	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Seizures associated with Tuberous Sclerosis Complex (TSC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2023	Apr 18, 2024	SR0798-000
nirmatrelvir/ritonavir	Paxlovid	nirmatrelvir/ritonavir	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Mild-to-moderate COVID-19, treatment	Reimburse with clinical criteria and/or conditions	Complete	Sep 15, 2023	Apr 11, 2024	SR0808-000
teclistamab	Tecvayli	teclistamab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Relapsed or refractory multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Aug 31, 2023	Apr 8, 2024	PC0332-000
drospirenone	Slynd	drospirenone	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Contraceptive, oral	Reimburse with clinical criteria and/or conditions	Complete	Aug 14, 2023	Mar 18, 2024	SR0806-000
ravulizumab	Ultomiris	ravulizumab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Neuromyelitis optica spectrum disorder (NMOSD)	Reimburse with clinical criteria and/or conditions	Complete	Aug 29, 2023	Mar 13, 2024	SR0785-000
inebilizumab	Uplizna	inebilizumab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Neuromyelitis optica spectrum disorders (NMOSD)	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2023	Mar 13, 2024	SR0793-000
sotorasib	Lumakras	sotorasib	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	KRAS G12C-mutated advanced NSCLC	Do not reimburse	Complete	Aug 19, 2022	Feb 29, 2024	PC0300-000
trifluridine and tipiracil	Lonsurf	trifluridine and tipiracil	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Metastatic colorectal cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 15, 2023	Feb 29, 2024	PC0330-000
treosulfan	Trecondyv	treosulfan	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)	Reimburse with clinical criteria and/or conditions	Complete	Jul 14, 2023	Feb 28, 2024	PC0324-000
fidanacogene elaparvovec	Beqvez	fidanacogene elaparvovec	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Hemophilia B	Reimburse with clinical criteria and/or conditions	Complete	Aug 1, 2023	Feb 16, 2024	SG0802-000
belumosudil	Rezurock	belumosudil	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Graft-versus-host disease	Reimburse with clinical criteria and/or conditions	Complete	Jul 26, 2023	Feb 15, 2024	SR0789-000
odevixibat	Bylvay	odevixibat	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Progressive familial intrahepatic cholestasis (PFIC)	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2023	Feb 13, 2024	SR0788-000
nivolumab and relatlimab	Opdualag	nivolumab and relatlimab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	unresectable or metastatic melanoma	Reimburse with clinical criteria and/or conditions	Complete	Jul 10, 2023	Feb 2, 2024	PC0329-000
glofitamab	Columvi	glofitamab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Relapsed or refractory diffuse large B-cell lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Jul 18, 2023	Feb 2, 2024	PC0320-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 76 - 100 of 600

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Somatropin		Final Report	Jul 12, 2024	Technology Review	Completed	HC0068-000
Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy	Our utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada.	Final Report	Jul 11, 2024	Technology Review	Complete	HC0063-000
Optimal installation of DI equipment			Jun 28, 2024		In Progress	CM0013-000
Appraisal of RWE submitted for health technology assessment			Jun 28, 2024		In Progress	MG0028-000
PET-CT Comparisons 2020-2024			Jun 28, 2024		In Progress	CM0006-000
Cystic Fibrosis			Jun 28, 2024		In Progress	HM0005-000
Newborn screening - Drugs for Rare Diseases Strategy			Jun 28, 2024	Technology Review	In Progress	HC0079-000
Methodology for Ethics Analysis in Pharmaceutical Reimbursement Reviews			Jun 28, 2024		In Progress	MG0027-000
Choline Supplementation for Infants, Children, and Pregnant People		Choline Supplementation for Infants, Children, and Pregnant People	Jun 18, 2024	Rapid Review	Completed	RC1531-000
Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome		Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome	Jun 17, 2024	Rapid Review	Completed	RC1540-000
Nabilone for Chronic Non-Cancer Pain		Nabilone for Chronic Non-Cancer Pain	Jun 14, 2024	Rapid Review	Completed	RC1539-000
Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities		Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities	Jun 14, 2024	Rapid Review	Completed	RC1536-000
Minimum Retesting Intervals for Lab Tests	Canada’s Drug Agency partnered with Choosing Wisely Canada to host a multidisciplinary panel of experts to provide guidance on the minimum retesting intervals of laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.	Final Guidance Report Technology Review - Minimum Retesting Intervals for Lab Tests Lipase Quick Guide Hemoglobin A1C Quick Guide Thyroid Stimulating Hormone Quick Guide Serum Protein Electrophoresis Quick Guide Antinuclear Antibody Quick Guide	Jun 11, 2024	Technology Review	Completed	HC0078-000
Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy		Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy	Jun 7, 2024	Rapid Review	Completed	RC1534-000
Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evaluation		Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evalua…	May 31, 2024	Technology Review	Completed	MH0020-000
Alemtuzumab, Cladribine, Fingolimod, and Natalizumab as First-Line Treatments in Adult Patients With Highly Active Relapsing Multiple Sclerosis		Final Report Project Protocol	May 30, 2024	Health Technology Assessment	Completed	HT0038-000
Drugs for Advanced Renal Cell Carcinoma: A Treatment Pattern Analysis			May 22, 2024	Technology Review	Active	HC0082-000
Newborn Screening for Congenital Cytomegalovirus in Canada	Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood hearing loss. Our report provides a summary about newborn screening for cCMV in Canada, including whether screening is available in each province and territory, and if so, whether screening is universal or targeted.	Final Report	May 22, 2024	Policy Insight	Completed	CY0016-000
Newborn Screening for Congenital Cytomegalovirus		Newborn Screening for Congenital Cytomegalovirus	May 17, 2024	Rapid Review	Completed	RC1533-000
Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide-1 Receptor Agonists		Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide…Final Summary Report	May 16, 2024	Technology Review	Completed	HC0087-000
Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)		Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)	May 7, 2024	CMII Service	Completed	CM0010-000
General Ultrasound Examination Volumes per Sonographer 8-Hour Workday		General Ultrasound Examination Volumes per Sonographer 8-Hour Workday	May 7, 2024	CMII Service	Completed	CM0012-000
Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada		Final Report, April 2024 Summary Report, April 2024	May 3, 2024	Technology Review	Completed	HC0069-000
Efficacy and Safety of Long-Term Use of Omalizumab for the Treatment of Chronic Idiopathic Urticaria		Final Report Final Summary Report Project Protocol	May 2, 2024	Systematic Review	Active	RE0043-000
SGLT2 inhibitors for the treatment of type 2 diabetes			Apr 18, 2024	Technology Review	Cancelled	HC0049-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 76 - 100 of 110

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
New Mechanical Thrombectomy Devices Designed to Treat Venous Thromboembolism	en0023-mechanical-thrombectomy-devices-article.pdf	Oct 22, 2020	Health Technology Update	Completed	EN0023-000
Non-Invasive Ventilation With Helmets for Acute Respiratory Distress Due to COVID-19	Non-Invasive Ventilation With Helmets for Acute Respiratory Distress Due to COV…	Sep 29, 2020	Health Technology Update	Completed	EN0020-000
Robotic Systems for Disinfecting Surfaces in Hospital Rooms and Other Health Care Environments	en0018-robotic-systems-for-disinfecting-surfaces.pdf	Sep 9, 2020	Health Technology Update	Completed	EN0018-000
A Virtual Waiting Room? Technologies That Limit Contact While Maintaining Patient Flow in Medical Practice Settings	en0019-topic1.pdf	Aug 21, 2020	Health Technology Update	Completed	EN0019-000
Salt-Based Technologies to Help Stop the Spread of the Coronavirus		Jun 23, 2020	Health Technology Update	Completed	EN0017-000
Biomarker-Based Point-of-Care Tests for the Evaluation of Mild Traumatic Brain Injury		Jun 23, 2020	Emerging Health Technologies	Completed	EH0084-000
Blood Purification Using Cytokine Adsorbers to Reduce Cytokine Storm in Severe COVID-19 Illness		Jun 18, 2020	Health Technology Update	Completed	EN0017-000
Health Technology Update Issue 26		Jun 12, 2020			EN0016-000
Saliva-Based Tests to Detect Active Severe Acute Respiratory Syndrome Coronavirus 2 Infection		Jun 3, 2020	Health Technology Update	Completed	EN0017-000
Contact Tracing Apps to Identify Potential Exposure to SARS-CoV-2		May 20, 2020	Health Technology Update	Completed	EN0017-000
Health Technology Update - Issue 27		May 20, 2020			EN0017-000
Health Technology Update Issue 27	en0017-htu-issue27.pdf	May 20, 2020			EN0017-000
Smartphone-Connected Ultrasound Devices		Apr 3, 2020	Emerging Health Technologies	Completed	Eh0079-000
Early Identification of Ischemic Stroke		Mar 19, 2020	Emerging Health Technologies	Completed	EH0080-000
Endobronchial Valves for the Treatment of Severe Emphysema		Mar 19, 2020	Emerging Health Technologies	Completed	EH0083-000
Small Molecule Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine		Mar 19, 2020	Emerging Health Technologies	Completed	EH0081-000
Lasmiditan for the Acute Treatment of Migraine		Mar 17, 2020	Emerging Health Technologies	Completed	EH0082-000
Horizon Scan Roundup — 2019		Mar 13, 2020	Roundup	Completed	ER0008-000
Minimally invasive therapies for benign prostatic hyperplasia (BPH)		Feb 18, 2020	Emerging Health Technologies	Completed	EH0078-000
Health Technology Update - Issue 26		Feb 7, 2020		Completed	EN0016-000
Magnetic Resonance-Guided Radiotherapy: MR-Simulation and MR-Linac		Jan 16, 2020	Emerging Health Technologies	Completed	EH0074-000
Magnetic Resonance Guided Radiotherapy: MR-simulation, and MR-linac		Jan 15, 2020		Completed	EH0074-000
Health Technology Update Issue 25		Jan 10, 2020			EN0015-000
Inclisiran: A Small Interfering RNA Molecule for Treating Hypercholesterolemia		Dec 9, 2019	Emerging Health Technologies	Completed	EH0076-000
Health Technology Update - Issue 25		Nov 11, 2019		Completed	EN0015-000

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 76 - 100 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
ferric carboxymaltose	Recommendation and Reasons Patient and Clinican Group Input	Apr 8, 2025	Reimbursement Review		Active	SR0842-000
spesolimab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Apr 7, 2025	Reimbursement Review		Complete	SR0844-000
faricimab	Recommendation and Reasons Patient and Clinician Group input	Apr 7, 2025	Reimbursement Review		Active	SR0832-000
exagamglogene autotemcel	Recommendation and Reasons Patient and Clinician Group Input	Apr 7, 2025	Reimbursement Review		Active	SG0831-000
exagamglogene autotemcel	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Apr 7, 2025	Reimbursement Review		Complete	SG0830-000
daratumumab	Draft Recommendations & Reasons Patient and Clinician Group input	Apr 7, 2025	Reimbursement Review		Active	PC0388-000
trastuzumab deruxtecan	Draft Recommendation Patient and Clinician Group Input	Apr 7, 2025	Reimbursement Review		Active	PC0367-000
Utilization of Antidiabetic Drugs During Pregnancy	Utilization of Antidiabetic Drugs During Pregnancy Summary Report	Apr 4, 2025	Health Technology Review	Technology Review	Active	HC0083-000 — OS0007-000
Aripiprazole	Proposed Scope	Apr 4, 2025	Reimbursement Review		Received	SX0756-000
Non-small-cell lung cancer (NSCLC)	Final Report	Apr 4, 2025	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0071-000
Myelofibrosis	Final Report	Apr 4, 2025	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0069-000
fruquintinib	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Apr 4, 2025	Reimbursement Review		Complete	PC0352-000
roflumilast		Apr 3, 2025	Reimbursement Review		Pending	SR0887-000
trametinib	Recommendations & Reasons Responses to the Questions from the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient, Clinician and Industry Input Combined Report Supplemental Materials Feedback on Draft Recommendation	Apr 3, 2025	Reimbursement Review		Complete	PX0372-000
pemigatinib	Draft Recommendation and Reasons Patient and Clinician Group input	Apr 3, 2025	Reimbursement Review		Active	PC0391-000
blinatumomab	Draft Recommendations & Reasons Patient and Clinician Group input	Apr 3, 2025	Reimbursement Review		Active	PC0365-000
durvalumab, carboplatin, paclitaxel	Draft Recommendation and Reasons Patient and Clinician Group input	Apr 3, 2025	Reimbursement Review		Active	PC0366-000
Appropriate Use of Antipsychotics in Long-Term Care		Apr 2, 2025	Health Technology Review	Technology Review	Active	HC0095-000
trastuzumab deruxtecan		Apr 2, 2025	Reimbursement Review		Pending	PC0401-000
Urothelial carcinoma	Final Report	Apr 1, 2025	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0070-000
Midline Catheters for Administering Intravenous Infusion Therapy	Midline Catheters for Administering Intravenous Infusion Therapy	Apr 1, 2025	Health Technology Review	Rapid Review	Completed	RC1572-000
lisocabtagene maraleucel	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Apr 1, 2025	Reimbursement Review		Complete	PG0358-000
ciltacabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Apr 1, 2025	Reimbursement Review		Complete	PG0361-000
Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis	Final Protocol Final Report Summary Report	Mar 31, 2025	Health Technology Review	Technology Review	Completed	HC0081-000
upadacitinib		Mar 31, 2025	Reimbursement Review		Pending	SR0877-000